Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that's been cleared for use in adults in parts of the ...

Results from the phase 4 COMPARE study indicate that Nuvaxovid exhibits a more favorable reactogenicity profile compared with the mNEXSPIKE mRNA vaccine.

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein ...

Add Yahoo as a preferred source to see more of our stories on Google. Samsung Biologics will conduct a simulated outbreak response using wild-type H5 influenza as a prototype pathogen The Coalition ...